» Articles » PMID: 9585014

Protein Composition of Synthetic Surfactant Affects Gas Exchange in Surfactant-deficient Rats

Overview
Journal Pediatr Res
Specialties Biology
Pediatrics
Date 1998 May 19
PMID 9585014
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Synthetic surfactant peptides offer an opportunity to standardize the protein composition of surfactant. We tested the effect of phospholipids (PL) with synthetic full-length SP-B1-78 (B), mutant B (Bser), KL4 peptide (UCLA-KL4), and palmitoylated SP-C1-35 (C) on oxygenation and lung function in a surfactant-deficient rat model. Sixty-four adult rats were ventilated with 100% oxygen, a tidal volume of 7.5 mL/kg, and a rate of 60/min. Their lungs were lavaged with saline until the arterial PO2 dropped below 80 torr, when 100 mg/kg surfactant was instilled. Surfactant preparations included: PL (PL surfactant), PL + 3% B (B surfactant), PL + 3% B and 1% C (BC surfactant), PL + 3% UCLA-KL4 (KL4 surfactant), PL + 3% Bser (Bser surfactant), and PL + 3% B and 1% UCLA-KL4 (BKL4 surfactant). Sixty minutes after surfactant instillation, positive end-expiratory pressure was applied for 5 min, and pressure-volume curves were determined in situ. The six surfactant preparations had a minimum surface tensions <10 mN/m on a Langmuir/Wilhelmy balance. Instillation of PL, Bser, and BKL4 surfactant increased mean arterial/alveolar PO2 (aADO2) ratios by 50-100% over postlavage values, whereas KL4 surfactant increased aADO2 ratios by 118%, B surfactant by 191%, and BC surfactant by 225%. Lung volumes at 30 cm H2O pressure were highest after treatment with BC surfactant, intermediate after B and KL4 surfactants, and lowest after BKL4, Bser, and PL surfactants. These data suggest that a surfactant preparation with a combination of synthetic B and C peptides surpasses synthetic B and KL4 surfactants in improving oxygenation and lung compliance in surfactant-deficient rats.

Citing Articles

Molecular Pathogenesis of Fibrosis, Thrombosis and Surfactant Dysfunction in the Lungs of Severe COVID-19 Patients.

Krygier A, Szmajda-Krygier D, Swiechowski R, Pietrzak J, Wosiak A, Wodzinski D Biomolecules. 2022; 12(12).

PMID: 36551272 PMC: 9776352. DOI: 10.3390/biom12121845.


Revisiting the role of pulmonary surfactant in chronic inflammatory lung diseases and environmental exposure.

Milad N, Morissette M Eur Respir Rev. 2021; 30(162).

PMID: 34911693 PMC: 9489000. DOI: 10.1183/16000617.0077-2021.


Effective in vivo treatment of acute lung injury with helical, amphipathic peptoid mimics of pulmonary surfactant proteins.

Czyzewski A, McCaig L, Dohm M, Broering L, Yao L, Brown N Sci Rep. 2018; 8(1):6795.

PMID: 29717157 PMC: 5931611. DOI: 10.1038/s41598-018-25009-3.


Aerosol delivery of synthetic lung surfactant.

Walther F, Hernandez-Juviel J, Waring A PeerJ. 2014; 2:e403.

PMID: 24918030 PMC: 4045332. DOI: 10.7717/peerj.403.


Synthetic surfactant containing SP-B and SP-C mimics is superior to single-peptide formulations in rabbits with chemical acute lung injury.

Walther F, Hernandez-Juviel J, Gordon L, Waring A PeerJ. 2014; 2:e393.

PMID: 24883253 PMC: 4034647. DOI: 10.7717/peerj.393.